Fineline Cube

Follow:
14435 Articles
AbbVie Reports Strong Q2 2025 Results With Immunology Portfolio Leading Growth
Company

AbbVie Reports Strong Q2 2025 Results With Immunology Portfolio Leading Growth

BMS Q2 Earnings Reflect Strategic Investments; Maintains Full-Year Revenue Growth Outlook
Company

BMS Q2 Earnings Reflect Strategic Investments; Maintains Full-Year Revenue Growth Outlook

China's NHSA Issues Rules for Instant Settlement of Medical Insurance Funds
Policy / Regulatory

China’s NHSA Issues Rules for Instant Settlement of Medical Insurance Funds

Hybio and BrightGene Partner on Peptide Raw Material Supply for Global Drug Commercialization
CompanyDeals

Hybio and BrightGene Partner on Peptide Raw Material Supply for Global Drug Commercialization

BeOne Medicines' BGB-16673 Granted PRIME Designation by EMA for Waldenström's Macroglobulinemia
CompanyDrug

BeOne Medicines’ BGB-16673 Granted PRIME Designation by EMA for Waldenström’s Macroglobulinemia

Neurodawn's Subsidiary Receives NMPA Approval for First LHI Treatment RK-4 Injection
CompanyDrug

Neurodawn’s Subsidiary Receives NMPA Approval for First LHI Treatment RK-4 Injection

NMPA Seeks Public Feedback on Draft Regulations for Internet Drug and Medical Device Information Services
Policy / Regulatory

NMPA Seeks Public Feedback on Draft Regulations for Internet Drug and Medical Device Information Services

Haisco's Ciprofol NDA Accepted by FDA: A Milestone for Chinese Anesthesia Innovation
CompanyDrug

Haisco’s Ciprofol NDA Accepted by FDA: A Milestone for Chinese Anesthesia Innovation

AstraZeneca's Ultomiris Gains NMPA Approval for Neuromyelitis Optica Spectrum Disorder
CompanyDrug

AstraZeneca’s Ultomiris Gains NMPA Approval for Neuromyelitis Optica Spectrum Disorder

Chipscreen's Next-Gen Brain-Penetrant Aurora B Inhibitor CS231295 Gains FDA Clearance for Advanced Solid Tumors
CompanyDrug

Chipscreen’s Next-Gen Brain-Penetrant Aurora B Inhibitor CS231295 Gains FDA Clearance for Advanced Solid Tumors

Hengrui Receives Clinical Clearance for HRS-5041 in Prostate Cancer Treatment
CompanyDrug

Hengrui Receives Clinical Clearance for HRS-5041 in Prostate Cancer Treatment

Porton Advanced and Cellstore Partner to Optimize Cell Therapy Drug Cryopreservation
CompanyDeals

Porton Advanced and Cellstore Partner to Optimize Cell Therapy Drug Cryopreservation